|
Jul 24
|
Personalis to Announce Second Quarter 2024 Financial Results
|
|
Jun 18
|
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
|
|
Jun 4
|
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
|
|
May 31
|
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
|
|
May 22
|
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
|
|
May 9
|
Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Is Personalis (NASDAQ:PSNL) In A Good Position To Deliver On Growth Plans?
|
|
May 9
|
Personalis First Quarter 2024 Earnings: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023)
|
|
May 9
|
Q1 2024 Personalis Inc Earnings Call
|
|
May 9
|
Personalis Inc (PSNL) (Q1 2024) Earnings Call Transcript Highlights: Surpassing Revenue ...
|
|
May 8
|
Personalis Reports First Quarter 2024 Financial Results
|
|
Apr 24
|
Personalis to Announce First Quarter 2024 Financial Results
|
|
Mar 28
|
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 28
|
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
|
|
Mar 26
|
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
|
|
Mar 19
|
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 29
|
Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call Transcript
|
|
Feb 28
|
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Jan 16
|
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
|
|
Dec 18
|
Even With A 37% Surge, Cautious Investors Are Not Rewarding Personalis, Inc.'s (NASDAQ:PSNL) Performance Completely
|